Back to Search Start Over

Dual versus Single Antiplatelet Therapy in Carotid Artery Endarterectomy: Direct Comparison of Complications Related to Antiplatelet Therapy.

Authors :
Jiang, Qun-Long
Wang, Pei-Jian
Liu, Hui-Xin
Huang, Li-Li
Kang, Xiao-Kui
Source :
World Neurosurgery. Mar2020, Vol. 135, pe598-e609. 12p.
Publication Year :
2020

Abstract

Dual and single antiplatelet therapies are routinely used in carotid artery endarterectomy (CEA). However, the efficacy and safety of these therapies are controversial. The present study aimed to comprehensively compare the clinical outcomes between dual and single antiplatelet therapies in CEA. This study retrieved available academic studies evaluating the complications related to antiplatelet therapy between dual and single antiplatelet therapies in CEA from the databases of ScienceDirect, the Cochrane Library, EMBASE, and PubMed. References to previous reviews and related clinical trials were manually checked to retrieve potential literature that was not included in our electronic search results. A total of 10 articles (1 randomized controlled trial, 9 non-randomized controlled trials) were included in the study. The overall number of patients in the dual antiplatelet group was 14,280, and the number of patients in the single antiplatelet group was 125,850. The results revealed that the single antiplatelet group had a lower incidence of 30-day death (rate difference [RD] 0.002; 95% confidence interval [CI] 0.000–0.003; P = 0.014), neck hematoma (odds ratio [OR] 2.120; 95% CI 1.431–3.142; P < 0.001), myocardial infarction (RD 0.004; 95% CI 0.001–0.007; P = 0.003), and major bleeding (RD 0.005; 95% CI 0.002–0.008; P < 0.001). Meanwhile, the single antiplatelet group was associated with a shorter operation time (weighted mean difference 4.000; 95% CI= 2.564–5.436; P < 0.001). However, there was no significant difference in the rate of postoperative transient ischemic attack (P = 0.215), stroke (P = 0.130), or length of stay (P = 0.563). Based on current evidence, using single antiplatelet therapy in CEA may reduce operation time and the incidences of 30-day death, neck hematoma, major bleeding, and myocardial infarction without increasing the risks of transient ischemic attack, stroke, or a longer operation time. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
18788750
Volume :
135
Database :
Academic Search Index
Journal :
World Neurosurgery
Publication Type :
Academic Journal
Accession number :
142023743
Full Text :
https://doi.org/10.1016/j.wneu.2019.12.070